BNP Health Care Innovators is an actively managed equity fund with a track record going back to 2013. The management company is BNP Paribas Asset Management, the asset management arm of the French banking group BNP Paribas. The company was expanded through the acquisition of AXA Investment Managers on 1 July 2025 and is owned by BNP Paribas Cardif.
Investment philosophy
The fund buys shares in companies worldwide that enable or benefit from innovative technologies in health care. The mandate mentions genetic sequencing, drug delivery, miniaturisation, bio-compatible materials, haptics and information technology, but is not limited to these. Selection therefore follows technology and innovation, in a growth-oriented thematic approach. ESG criteria contribute to the managers' decisions but are not decisive.
The managers
The fund is managed by a team at BNP Paribas Asset Management in Boston, with shared responsibility. Jon Stephenson has managed the fund since 2016 and is lead manager of the Health Care Innovators strategy. He came from Pioneer Investments, where he managed growth strategies, and has a background as a health care analyst at State Street Research. Christian Fay has managed the fund since 2018. He was also at BNP Paribas Asset Management in 2013–2015 before moving to Mellon, and returned in 2018. He has a background as a health care analyst at Amundi and Leerink Swann, and holds master's degrees in biology and public health as well as an MBA. Fay also manages funds such as BNP US Growth and BNP US Small Cap.
The portfolio
The selection is global and bounded by the innovation theme, not by country.
Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.